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1164Objectives:We sought to determine the prognostic significance of extralobar nodal metastases versus intralobar
nodal metastases in patients with lung cancer and pathologic stage N1 disease.
Methods: A retrospective review of a prospectively maintained lung resection database identified 230 patients
with pathologic stage II, N1 non–small cell lung cancer from 1997 to 2011. The surgical pathology reports were
reviewed to identify the involved N1 stations. The outcome variables included recurrence and death. Univariate
and multivariate analyses were performed using the R statistical software package.
Results:A total of 122 patients had extralobar nodal metastases (level 10 or 11); 108 patients were identifiedwith
intralobar nodal disease (levels 12-14). Themedian follow-upwas 111months. The baseline characteristics were
similar in both groups. No significant differences were noted in the surgical approach, anatomic resections per-
formed, or adjuvant therapy rates between the 2 groups. Overall, 80 patients developed recurrence during follow-
up: 33 (30%) of 108 in the intralobar and 47 (38%) of 122 in the extralobar cohort. The median overall survival
was 46.9 months for the intralobar cohort and 24.4 months for the extralobar cohort (P<.001). In a multivariate
Cox proportional hazard model that included the presence of extralobar nodal disease, age, tumor size, tumor
histologic type, and number of positive lymph nodes, extralobar nodal disease independently predicted both
recurrence-free and overall survival (hazard ratio, 1.96; 95% confidence interval, 1.36-2.81; P ¼ .001).
Conclusions: In patients who underwent surgical resection for stage II non–small cell lung cancer, the presence
of extralobar nodal metastases at level 10 or 11 predicted significantly poorer outcomes than did nodal
metastases at stations 12 to 14. This finding has prognostic importance and implications for adjuvant therapy
and surveillance strategies for patients within the heterogeneous stage II (N1) category. (J Thorac Cardiovasc
Surg 2014;147:1164-8)In the evaluation and management of non–small cell lung
cancer (NSCLC), accurate staging is critical for appropriate
medical and surgical management. The identification of
nodal metastases has formed the basis for prognostic
stratification in patients eligible for resection. The presence
of N1 nodal metastasis will reduce the 5-year survival from
56% to 38% compared with node-negative disease.1
The N1 classification is anatomically heterogeneous,
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The Journal of Thoracic and Cardiovascular Sur(level 12), and segmental and subsegmental (level 13 and
14) nodes.2 Given this anatomic heterogeneity, a number
of studies have sought to investigate further the anatomic
stations within the N1 classification in the hopes of refining
the nodal staging schema for better prognostic stratifica-
tion.3-11 Many of these studies have identified trends
toward worse outcomes with more anatomically central
nodal involvement; however, the data have remained
inconclusive. Most of these studies have included patients
with advanced (T3-T4) primary tumors and N1 disease.
This has likely obscured some of the prognostic effects of
the nodal metastases, because the effect of N1 disease has
been shown to dissipate with advanced T stages.4,5
The most recent of these studies analyzed 522 patients
with stage N1 disease of the 2876 evaluable patients in
the International Association for the Study of Lung Cancer
Staging Project for Lung Cancer.1 Although that analysis
was not sufficient to change the N1 staging system, a trend
was seen toward decreased survival with positive level 10
nodes in contrast to positive level 12 nodes. Because only
380 of the patients were from North America, positron
emission tomography was not used, and surgical therapy
was not standardized, we sought to perform a similargery c April 2014
Abbreviation and Acronym
NSCLC ¼ non–small cell lung cancer
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Sanalysis using our single-institution database. In addition,
we examined the effect of anatomic nodal station on
survival within the N1 classification by focusing on patients
with stage II, T1-T2N1, minimizing the confounding effects
of T stage on the outcome.
METHODS
Reviewing the medical records of 1000 consecutive patients undergoing
lung resection at Duke University Medical Center from 1997 to 2011, we
identified 230 patients with stage II pN1 NSCLC (T1 and T2 tumors).
Clinical information was obtained from a review of the electronic medical
records after the institutional review board approved the study. All patients
had undergone surgery at Duke University Hospital with lung resection
and mediastinal lymphadenectomy. The surgical pathology reports were
reviewed and the lymph node stations categorized according to the
International Association for the Study of Lung Cancer TNM staging
system, with the lymph node levels identified as described by Mountain
and Dresler.2 Metastases to level N1 nodes and the lack of disease to N2
nodes were confirmed in each surgical pathology report. Extralobar lymph
node stations were defined as those removed separately and identified as
level 10 or 11 and those nodes identified by the pathologist as ‘‘hilar.’’
The pathologists uniformly used this designation when the lymph node
was clearly extraparenchymal. Intralobar nodal stations included nodes
removed and identified as level 12 and those identified within the specimen
as ‘‘parenchymal.’’ We defined our ‘‘intralobar’’ group as patients with
disease limited to stations 12 to 14 and our ‘‘extralobar’’ group as patients
with disease at level 10 or 11, independent of the presence or absence of
more peripheral nodal disease. We also performed a separate analysis in
which the patients with both intralobar and extralobar disease were
considered as a separate group. The follow-up period for the group ranged
from 0 to 133 months (mean, 111). Information was gathered on the
number of examined nodes and the number positive at each nodal station.
Additional clinical information was obtained regarding the use of adjuvant
chemotherapy and outcomes, including the timing and site of recurrences
and death. The Social Security Death Index was also queried to maximize
the information on overall survival.
Statistical Analysis
Comparisons between patient and treatment variables were made
and evaluated using Student t test, Fisher exact test, or chi-square
tests, as appropriate. Survival was calculated using the Kaplan-Meier
method, with between-group comparisons made using the log-rank test.
Multivariate analysis was conducted using a Cox proportional hazards
model. Statistical analysis was performed using the R statistical software
package (Free Software Foundation, Inc, Boston, Mass).
RESULTS
Of the 230 identified patients with stage II, pathologic N1
disease, 122 were identified with extralobar disease at
stations 10 and 11 and 108 as having lymph node metastases
confined to intralobar stations 12 to 14. Within the
extralobar group, a few (n ¼ 26) had additional peripheral
nodal metastases at the intralobar stations, but most
(n ¼ 96) had nodal disease confined to the extralobarThe Journal of Thoracic and Carstations. The baseline patient characteristics are listed in
Table 1. No significant differences between the 2 groups
were noted in age or pulmonary function as measured by
the diffusion capacity. Small, but statistically significant,
differences were noted in the forced vital capacity and
primary tumor size, leading to the latter’s inclusion in the
multivariate survival model.
The lymph node yield ranged from 1 to 26 nodes (mean,
6 recovered per patient). The positive lymph node rates
ranged from 1 to 12 (mean, 1.83 positive per patient).
Lobectomy was the most common surgical resection
procedure, performed in 168 (73%), followed by
pneumonectomy in 41 (18%). Bilobectomy (n ¼ 14,
6.1%) and segmentectomy (n ¼ 7, 3%) were performed
in a few patients. Thoracotomy was the primary surgical
approach overall, used in 132 patients (57%). As expected,
the surgical approach evolved over time. Before 2003,
thoracotomy was used in 82% of the resections; after
2003, thoracoscopy became the dominant approach. It
was used in 58% of patients, a percentage that stayed
relatively stable through the end of the study period.
Primary tumors were assessed for location, size,
histologic type, and grade. Right-sided lesions were slightly
more common (53%), with right upper lobe tumors
predominating (73%). Upper lobe tumors were also more
common on the left side (68%). All tumors were stage T1
or T2, with most (73%) being T2 lesions. Overall, the
mean tumor size was 3.3 cm. Adenocarcinoma (42%) and
squamous cell carcinoma (40%) were the dominant
histologic types. The tumors were graded as moderately
differentiated in 36%, poorly differentiated in 34%, and
well-differentiated in 5%.
Adjuvant chemotherapy was administered to 102 patients
(44%). As expected, its use increased over time, with the
application of adjuvant therapy increasing to 57% after
2007, despite all patients being referred for consideration
of adjuvant treatment.
The 2 groups were examined along multiple clinical
variables (Table 1). No statistically significant difference
was noted in the frequency of a thoracoscopic approach,
frequency of the various anatomic resections, or use
of adjuvant chemotherapy. The total lymph node yield
and number of positive lymph nodes have both been
demonstrated to predict survival.15 No significant
differences were identified in the total nodal yield or total
number of positive nodes (Figure 1). However, a significant
difference was seen in the histologic distribution of the
tumors. Adenocarcinoma and squamous cell carcinoma
remained the dominant histologic types in both groups;
however, adenocarcinoma occurred with greater frequency
in the extralobar metastasis group (46% vs 37%, P¼ .003),
with squamous cell carcinoma constituting a corres-
pondingly lower percentage (30% vs 50%, P < .001;
Table 1).diovascular Surgery c Volume 147, Number 4 1165
TABLE 1. Patient and clinical characteristics
Characteristic
Extralobar
positive
Intralobar
positive P value
Mean age (y) 63.3 65.8 .07
Mean FEV1 (% predicted) 68.6 75.2 .007
Mean DLCO (% predicted) 74.9 75.1 .98
Mean size (cm) 3.16 3.54 .05
VATS approach (%) 38.9 45.9 .29
Lobectomy (%) 75.0 71.3 .63
Adjuvant therapy (%) 44.3 44.4 .92
Histologic type (%) .003
Adenocarcinoma 46 37
Squamous cell carcinoma 30 50
FEV1, Forced expiratory volume in 1 second; DLCO, diffusing capacity of the lung
for carbon monoxide; VATS, video-assisted thoracic surgery.
TABLE 2. Clinical variables and cancer recurrence
Characteristic Recurrence rate (%) P value
Nodal disease .21
Extralobar 38.5
Intralobar 30.6
Adjuvant therapy .39
Yes 36.3
No 33.6
Surgical approach .77
VATS 40.0
Thoracotomy 31.1
Resection extent .21
Lobectomy 37.5
Pneumonectomy 27.0
Histologic type .07
Adenocarcinoma 43.2
Squamous cell carcinoma 30
VATS, Video-assisted thoracic surgery.
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Cancer recurrence occurred in 80 of the 230 patients.
Sixty percent of the recurrences occurred within the thorax,
although few (12%) of those were truly at the site of
previous resection. The remainder (48%) of intrathoracic
metastases included multifocal mediastinal adenopathy or
diffuse or contralateral parenchymal lesions. The remaining
metastases were distributed evenly among the skeletal,
brain, and abdominal lesions, with each comprising
approximately 12% of the cases.
Of the recurrences, 47 were observed among patients
with extralobar nodal disease (38%), and 33 were within
the intralobar cohort (30%). Additional factors, including
adjuvant chemotherapy, histologic type, surgical approach,
and anatomic resection, were assessed for their effect
on recurrence development (Table 2). No statistically
significant differences were noted in the recurrence rates,FIGURE 1. Comparison of total nodal harvest and positive node yield
stratified by nodal station. No significant difference in the mean lymph
node yield (P ¼ .17) or mean number of positive nodes (P ¼ .09) was
detected between the extralobar and intralobar disease groups.
1166 The Journal of Thoracic and Cardiovascular Suralthough adenocarcinoma showed a trend toward a greater
incidence of recurrence than squamous cell carcinoma
(P ¼ .07). Although the absolute recurrence rate was
not significantly different statistically according to the
nodal station on multivariate Cox model analysis, taking
into account the interval to recurrence, the presence of
extralobar nodal disease was a statistically significant
predictor of disease recurrence (hazard ratio, 1.83; 95%
confidence interval, 1.14-2.92; P ¼ .011).
Survival
Of the 230 patients, 137 died. Seven patients (3%) died in
the immediate perioperative period and were included in theFIGURE 2. Kaplan-Meier overall survival curves for patients with stage
II disease and extralobar (hilar ¼ 1, level 10 or 11 positive) or intralobar
(hilar¼ 0, levels 12-14 positive) nodal metastases. Log-rank test, P¼ .003.
gery c April 2014
TABLE 3. Cox proportional hazard models
Factor HR (95% CI) P value
Disease-free survival
Extralobar positive 1.83 (1.14-2.92) .01
Age (per y) 1.02 (0.99-1.04) .23
Tumor size 1.21 (1.03-1.42) .02
Number of positive nodes 0.92 (0.767-1.09) .34
Squamous cell histologic type 0.49 (0.289-0.823) .007
Overall survival
Extralobar positive 2.02 (1.40-2.91) .0001
Age (per y) 1.03 (1.01-1.05) .001
Tumor size 1.10 (0.971-1.24) .14
Number of positive nodes 0.87 (0.750-1.00) .053
Squamous cell histologic type 0.70 (0.469-1.05) .08
CI, Confidence interval; HR, hazard ratio.
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Scalculations. Survival was calculated for patients according
to the level of nodal involvement. Kaplan-Meier analysis
(Figure 2) demonstrated a statistically significant difference
in survival between patients with extralobar nodal disease
and intralobar nodal disease (P ¼ .003). Multivariate
models of disease-free and overall survival were con-
structed. The presence of extralobar nodal metastases at
level 10 or 11 predicted a poorer outcome (hazard ratio,
2.02; 95% confidence interval, 1.40-2.91; P ¼ .0001;
Table 3). The median overall survival was 46.9 months
for the intralobar cohort and 24.4 months for the
extralobar cohort. The 26 patients with both intralobar
and extralobar nodal disease fared the same as the patients
with extralobar disease alone.DISCUSSION
Thorough lymph node staging at anatomic resection has
become the standard of care for surgically managed
NSCLC. The presence of N1 nodal metastases will have a
significant effect on the prognosis, reducing the 5-year
survival by one third.1 In addition, the identification of N1
nodal metastases has therapeutic ramifications, because
patients with resected stage II NSCLC will benefit
from adjuvant chemotherapy.12 The current National
Comprehensive Cancer Network guidelines have recom-
mended 4 cycles of a platinum-based doublet for all patients
with resected N1-positive NSCLC.13 Within the N1
classification, however, the anatomic differences in nodal
station are significant. Level 10 hilar nodes abut the pleural
reflection and are in close proximity to the N2 mediastinal
nodal basins,14 and level 13 to 14 nodes are peripherally
encased within the parenchyma and can only be removed
entirely during anatomic lung resection.
Thus, multiple groups during the past 2 decades have
sought to reevaluate the N1 classification in an effort to
further parse survival into more accurate substrata. The
results have been mixed. Marra and colleagues5 and
Caldarella and colleagues3 found statistically significantThe Journal of Thoracic and Carreductions in 5-year survival with extralobar nodal disease,
andMaeshima and colleagues,6 Demir and colleagues,4 and
Rusch and colleagues1 failed to find outcomes that reached
statistical significance. However, these latter studies
demonstrated a trend toward worse survival with extralobar
disease. Although not a universal finding, multiple groups
have also demonstrated that multistation disease results in
a worse prognosis than single-station or single-node
disease.1,4
One of the more significant investigations of the N1 nodal
subgroups occurred in 2007, when the International
Association for the Study of Lung Cancer undertook
revision of the TNM staging system for its seventh edition.1
In that study, nodal disease was described by zone, with
peripheral intralobar stations 12 to 14 separated from the
‘‘hilar’’ or extralobar stations 10 and 11. Comparisons
were made between single- and multiple-zone lesions.
Although none reached statistical significance, a clinically
important trend was observed, with ‘‘hilar’’ zone lesions
demonstrating worse median survival than peripheral zone
lesions (P¼ .059). These results were insufficient to justify
a change to the N1 designation within the TNM staging
system.
In the present study, we used the same zone designations,
defined anatomically as extralobar (level 10 and 11) and
intralobar (levels 12-14) disease. Unlike the previously
cited studies, we have isolated the analysis to patients
with stage II to avoid potential confounding effects from
advanced T stage. Although some investigators have found
no effect of T stage in the presence of N1 disease, others
have found that T3 and T4 tumors eliminated the effect of
lobar versus hilar nodal disease on survival. Although these
latter studies found a survival advantage for lobar versus
hilar disease only in patients with stage II disease, the
outcomes of T3N1 and T4N1 disease were primarily
determined by the completeness of the resection.4,6 In
keeping with our hypothesis that extralobar disease is a
more powerful predictor of the outcome, our extralobar
designation was also defined by the highest level of nodal
disease and thus included 26 patients with both extra- and
intralobar disease. Importantly, we found no significant
differences in patient factors or the number of lymph
nodes harvested or positive, both factors found to affect
the outcome.15 We found no significant differences in the
modes of surgical therapy or approach. On multivariate
analysis, we found significant differences in the disease-
free and overall survival using the extralobar anatomic
division.
In addition, a statistically significant differencewas noted
in the histologic type of the tumors between nodal groups,
with a greater percentage of adenocarcinoma in the
extralobar nodal metastasis category. Adenocarcinoma
showed a trend toward greater recurrence rates compared
with squamous cell carcinoma. On multivariate analysis,diovascular Surgery c Volume 147, Number 4 1167
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cant protective effect on survival compared with other
histologic types. Although this finding is not novel,5 the
prevailing belief has been that the histologic type does not
have a significant differential effect on survival. The
inclusion of both factors in our multivariate Cox propor-
tional hazards model showed that the effect of the histologic
type on survival did not eliminate the effect of the presence
of extralobar nodal disease (Table 3). We found no effect of
adjuvant therapy on recurrence; however, our data on the
use of adjuvant therapy was hampered by the retrospective
nature of our review and the limited data available on the
specifics of treatment. Thus, our data were inadequate to
effectively assess the effect of adjuvant therapy.
In conclusion, we have demonstrated that, among
patients with surgically resected stage II NSCLC with N1
disease, the presence of extralobar nodal metastases at
levels 10 and 11 confers a poorer prognosis than does
nodal disease confined to intralobar nodes. This finding
underscores the importance of thorough and accurate hilar
lymph node dissection during lung resection. It has been
our institutional practice to remove and identify levels
10 and 11 separately for accurate staging. As a single-
institution retrospective review, our study had the
limitations of its retrospective nature, limited sample
size, and statistical power. Nevertheless, our findings
have potential therapeutic and prognostic significance.
Despite the recommendations for adjuvant platinum-based
chemotherapy, many patients will not receive this therapy
for a variety of reasons.16,17 Identifying a subset of
N1-positive patients at greater risk of recurrence would
help strengthen the recommendations and support a more
aggressive adjuvant treatment strategy for this population.
Furthermore, patients with extralobar disease could be
considered for trials of novel or additional adjuvant
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